The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Chongzhen Guo
Chengda Yan
Lianyue Qu
Rongrong Du
Jianyang Lin
机构：
[1] The First Hospital of China Medical University,Department of Pharmacy
[2] China Medical University,School of Pharmaceutical Science
来源：
Archives of Gynecology and Obstetrics | 2021年 / 303卷
关键词：
Angiogenesis inhibitors; Ovarian cancer; Progression-free survival; Overall survival; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：285 / 311
页数：26
相关论文
共 50 条
  • [31] Safety and efficacy of aspirin for primary prevention of cancer: a meta-analysis of randomized controlled trials
    Haykal, Tarek
    Barbarawi, Mahmoud
    Zayed, Yazan
    Yelangi, Anitha
    Dhillon, Harsukh
    Goranta, Sowmya
    Kheiri, Babikir
    Chahine, Adam
    Samji, Varun
    Kerbage, Josiane
    Katato, Khalil
    Bachuwa, Ghassan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (07) : 1795 - 1809
  • [32] Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials
    Wang, Yizi
    Zhang, Shitai
    Song, Zixuan
    Ouyang, Ling
    Li, Yan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [33] Antiangiogenesis therapy in ovarian cancer patients An updated meta-analysis for 15 randomized controlled trials
    Jiang, Yanyan
    Sun, Xiaomei
    Kong, Beihua
    Jiang, Jie
    MEDICINE, 2018, 97 (34)
  • [34] Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials
    Zhang, P.
    Li, C. -Z.
    Jiao, G. -M.
    Zhang, J. -J.
    Zhao, H. -P.
    Yan, F.
    Jia, S. -F.
    Hu, B. -S.
    Wu, C. -T.
    EJSO, 2017, 43 (07): : 1161 - 1172
  • [35] Immune checkpoints inhibitors and hyperglycemia: A Meta-analysis of randomized controlled trials
    Monami, Matteo
    Naletto, Lara
    Nreu, Besmir
    Dicembrini, Ilaria
    Sesti, Giorgio
    Mannucci, Edoardo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [36] Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
    Wei, Yan
    He, Li
    Liu, Tao
    Guo, Tao
    Xie, Cong
    Jia, Jigang
    Lin, Yonghong
    Liu, Jiang
    Fan, Jiayin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [37] Clinical efficacy of acupuncture for diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials
    Lin, Guangyao
    Liu, Xiyu
    Cong, Chao
    Chen, Siru
    Xu, Lianwei
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [38] Efficacy and safety of different angiogenesis inhibitors combined with PARP inhibitors in the treatment of ovarian cancer: A systematic review and meta-analysis
    Huang, Xuemei
    Luo, Jianxiu
    Gu, Liqin
    ONCOLOGY LETTERS, 2025, 29 (01)
  • [39] Incidence and risk of rash to mTOR inhibitors in cancer patients a meta-analysis of randomized controlled trials
    Shameem, Raji
    Lacouture, Mario
    Wu, Shenhong
    ACTA ONCOLOGICA, 2015, 54 (01) : 124 - 132
  • [40] Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
    Chen, Juying
    Wu, Xiaozhe
    Wang, Hongzhe
    Lian, Xiaoshan
    Li, Bing
    Zhan, Xiangbo
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2024, 20 (06) : 736 - 751
12345